BioKinetic Clinical Applications LLC
- Type
- Non-covered entity
- Where
- Newark, DE
- Received
- $2,406,662 in 97 records, 2019 to 2025 ($0 general, $2,406,662 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 19 | $169,397 |
| 2024 | Research payment | 36 | $454,874 |
| 2023 | Research payment | 33 | $773,941 |
| 2022 | Research payment | 3 | $761,504 |
| 2020 | Research payment | 1 | $54,926 |
| 2019 | Research payment | 5 | $192,017 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 90 | $1,420,337 | 2022–2025 |
| Biogen, Inc. | 1 | $739,381 | 2022 |
| DPT Laboratories, Ltd. | 3 | $240,422 | 2019–2020 |
| SANOFI PASTEUR INC. | 3 | $6,521 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 97 | $2,406,662 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-17 | PFIZER INC. | $22,130 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE | 2025 |
| 2025-11-27 | PFIZER INC. | $11,879 | Research payment | Cash or cash equivalent | A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN STUDY TO DESCRIBE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL | 2025 | |
| 2025-11-26 | PFIZER INC. | $2,168 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-11-13 | PFIZER INC. | $8,406 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE | 2025 |
| 2025-11-05 | PFIZER INC. | $44,135 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE | 2025 |
| 2025-11-04 | PFIZER INC. | $8,879 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F | 2025 |
| 2025-08-09 | PFIZER INC. | $4,517 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE | 2025 |
| 2025-07-30 | PFIZER INC. | $27,483 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE | 2025 |
| 2025-07-09 | PFIZER INC. | $20,900 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2025 |
| 2025-06-26 | PFIZER INC. | $1,668 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-06-21 | PFIZER INC. | $3,615 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-06-14 | PFIZER INC. | $1,112 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-06-04 | PFIZER INC. | $1,865 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2025 |
| 2025-03-22 | PFIZER INC. | $2,610 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2025 |
| 2025-01-29 | PFIZER INC. | $312 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-01-22 | PFIZER INC. | $1,873 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-01-15 | PFIZER INC. | $624 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2025-01-09 | PFIZER INC. | $3,966 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2025 |
| 2025-01-01 | PFIZER INC. | $1,249 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2025 | |
| 2024-12-31 | PFIZER INC. | $3,119 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-12-27 | PFIZER INC. | $1,300 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-12-25 | PFIZER INC. | $14,730 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2024 | |
| 2024-12-18 | PFIZER INC. | $2,871 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2024 | |
| 2024-12-05 | PFIZER INC. | $55,056 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE C | 2024 | |
| 2024-12-05 | PFIZER INC. | $2,331 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-10-16 | PFIZER INC. | $9,672 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-10-09 | PFIZER INC. | $806 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-10-05 | PFIZER INC. | $10,569 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-10-03 | PFIZER INC. | $34,424 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-10-03 | PFIZER INC. | $10,912 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-09-10 | PFIZER INC. | $124 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-08-27 | PFIZER INC. | $60,832 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-08-23 | PFIZER INC. | $4,546 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-08-23 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-07-06 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-05-29 | PFIZER INC. | $11,900 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-05-07 | PFIZER INC. | $855 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-04-26 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-04-20 | PFIZER INC. | $14,016 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-04-05 | PFIZER INC. | $23,220 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-04-05 | PFIZER INC. | $7,368 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-03-30 | PFIZER INC. | $75,110 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-03-29 | PFIZER INC. | $8,690 | Research payment | Cash or cash equivalent | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND | 2024 | |
| 2024-03-29 | PFIZER INC. | $1,499 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2024 | |
| 2024-03-27 | PFIZER INC. | $3,654 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-03-26 | PFIZER INC. | $11,530 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2024 | |
| 2024-03-14 | PFIZER INC. | $450 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-03-08 | PFIZER INC. | $8,456 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED | 2024 | |
| 2024-03-05 | PFIZER INC. | $9,225 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-02-23 | PFIZER INC. | $2,206 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-02-14 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2024 | |
| 2024-01-26 | PFIZER INC. | $311 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2024 |
| 2024-01-25 | PFIZER INC. | $6,806 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2024 |
| 2024-01-20 | PFIZER INC. | $47,925 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2024 | |
| 2024-01-11 | PFIZER INC. | $3,550 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2024 | |
| 2023-12-27 | PFIZER INC. | $14,345 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-12-21 | PFIZER INC. | $1,637 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-12-08 | PFIZER INC. | $4,055 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-12-07 | PFIZER INC. | $36,885 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-11-10 | PFIZER INC. | $8,286 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-11-09 | PFIZER INC. | $400 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2023 | |
| 2023-11-08 | PFIZER INC. | $12,091 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-10-26 | PFIZER INC. | $8,866 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-10-25 | PFIZER INC. | $22,767 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-10-21 | PFIZER INC. | $8,128 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-10-18 | PFIZER INC. | $52,117 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-10-07 | PFIZER INC. | $100,664 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FO | 2023 |
| 2023-09-20 | PFIZER INC. | $737 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2023 | |
| 2023-08-19 | PFIZER INC. | $58,687 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2023 | |
| 2023-08-09 | PFIZER INC. | $2,226 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-07-26 | PFIZER INC. | $99,323 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2023 | |
| 2023-07-26 | PFIZER INC. | $179 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-07-15 | PFIZER INC. | $93,750 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2023 | |
| 2023-07-11 | PFIZER INC. | $52,968 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-07-06 | PFIZER INC. | $7,486 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-29 | PFIZER INC. | $8,904 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-22 | PFIZER INC. | $9,307 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-22 | PFIZER INC. | $7,100 | Research payment | Cash or cash equivalent | A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRA | 2023 | |
| 2023-06-21 | PFIZER INC. | $100,250 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-06-14 | PFIZER INC. | $768 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-13 | PFIZER INC. | $9,600 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREF | 2023 |
| 2023-06-03 | PFIZER INC. | $1,920 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-10 | PFIZER INC. | $599 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-04-05 | PFIZER INC. | $904 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-03-07 | PFIZER INC. | $2,367 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-02-28 | PFIZER INC. | $14,204 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-02-07 | PFIZER INC. | $6,173 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-01-11 | PFIZER INC. | $26,238 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2022-12-21 | PFIZER INC. | $10,803 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-11-23 | PFIZER INC. | $11,320 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2022 | |
| 2022-03-09 | Biogen, Inc. | $739,381 | Research payment | Cash or cash equivalent | ADUHELM Biological, Neurology | A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses o | 2022 |
| 2020-04-03 | DPT Laboratories, Ltd. | $54,926 | Research payment | Cash or cash equivalent | BDRF-18054 | 2020 | |
| 2019-05-29 | DPT Laboratories, Ltd. | $124,864 | Research payment | Cash or cash equivalent | BDRF-18054 | 2019 | |
| 2019-04-30 | DPT Laboratories, Ltd. | $60,631 | Research payment | Cash or cash equivalent | BDRF-18054 | 2019 | |
| 2019-03-26 | SANOFI PASTEUR INC. | $3,663 | Research payment | Cash or cash equivalent | DENGVAXIA Drug, VACCINES | CYD01 RANDOMIZED DOUBLE-BLIND PHASE I TRIAL OF THE COMPARATIVE SAFETY TOLERABILITY AND IMMUNOGENICITY OF CHIMERIVAXTm DE | 2019 |
| 2019-03-26 | SANOFI PASTEUR INC. | $1,468 | Research payment | Cash or cash equivalent | DENGVAXIA Drug, VACCINES | CYD01 RANDOMIZED DOUBLE-BLIND PHASE I TRIAL OF THE COMPARATIVE SAFETY TOLERABILITY AND IMMUNOGENICITY OF CHIMERIVAXTm DE | 2019 |
| 2019-03-26 | SANOFI PASTEUR INC. | $1,390 | Research payment | Cash or cash equivalent | DENGVAXIA Drug, VACCINES | CYD01 RANDOMIZED DOUBLE-BLIND PHASE I TRIAL OF THE COMPARATIVE SAFETY TOLERABILITY AND IMMUNOGENICITY OF CHIMERIVAXTm DE | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Newark, DE, county New Castle County, DE, state Delaware; placed by its city name.
| Measure | Place (city or town) Newark, DE | County New Castle County, DE | State Delaware |
|---|---|---|---|
| Population B01003 | 30,330 | 577,961 | 1,021,191 |
| Population, 2020 census P1 | 30,601 | 570,719 | 989,948 |
| Median age B01002 | 22.1 | 39.3 | 41.6 |
| Under 18 B01001 | 11.4% | 21.2% | 20.7% |
| 65 and over B01001 | 11.2% | 17.1% | 20.6% |
| Households B11001 | 8,594 | 224,173 | 402,038 |
| Foreign born B05002 | 12.9% | 12.8% | 10.7% |
| Median household income B19013 | $76,912 | $91,166 | $84,954 |
| Median family income B19113 | $131,398 | $114,354 | $105,121 |
| Per capita income B19301 | $35,264 | $47,777 | $45,375 |
| Poverty rate B17001 | 27.7% | 10.1% | 10.4% |
| Unemployment rate B23025 | 6.7% | 4.8% | 5.1% |
| Civilian labor force B23025 | 14,256 | 307,946 | 514,286 |
| Mean commute (minutes) B08013 | 19.0 | 25.3 | 26.0 |
| Bachelor's degree or higher B15003 | 58.2% | 39.7% | 35.8% |
| Housing units B25001 | 9,921 | 236,079 | 464,203 |
| Owner-occupied B25003 | 50.7% | 69.0% | 73.0% |
| Renters B25003 | 49.3% | 31.0% | 27.0% |
| Median home value B25077 | $382,500 | $352,200 | $352,000 |
| Median gross rent B25064 | $1,654 | $1,448 | $1,401 |
| White, not Hispanic B03002 | 65.5% | 52.3% | 58.1% |
| Black B03002 | 9.9% | 24.9% | 21.4% |
| Hispanic or Latino B03002 | 10.3% | 11.8% | 11.0% |
| Asian B03002 | 8.9% | 6.2% | 4.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.0% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (5.2% a year earlier); per capita personal income $68,630 in 2025, up 24% in five years (-0.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Newark, DE.
Comments